RxDoctor Payments Data

Francis Okeke, MD

Gastroenterology · El Paso, TXNPI 1386802957

Payments from drug & device makers

$1,703in general payments, 2019–2025

Across 99 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Takeda Pharmaceuticals U.S.A., Inc.$226
  • Ardelyx, Inc.$134
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$97
  • Pfizer$71
  • E.r. Squibb & Sons, L.L.C.$65
  • plus $371 from 10 others

What the payments were for

  • Food & beverage$1,703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,703 in reported general payments places this provider in the 30th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$216,342
Medicare patients
428
Services billed
2,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin68$220,244
MavyretGlecaprevir/Pibrentasvir11$141,771
LinzessLinaclotide224$130,063
CreonLipase/Protease/Amylase43$73,394
IbsrelaTenapanor Hcl39$71,310
Sucralfate262$12,150
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C87$11,820
VoqueznaVonoprazan Fumarate12$7,615
MotegrityPrucalopride Succinate11$6,215
TrulancePlecanatide11$6,032
Rifabutin52$5,189
Dicyclomine Hcl202$4,119
Pantoprazole Sodium492$3,488
Omeprazole312$3,477
Mesalamine25$3,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieMavyret, Linzess, Creon$737$345,228278 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu, Trulance$97$238,096166 claims
Ardelyx, Inc.Ibsrela$134$71,31039 claims
Phathom Pharmaceuticals, Inc.Voquezna$44$7,61512 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$226$6,21511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →